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Wemechanisticallyexplored theeﬀect ofincreased hydrophobicity ofthe polycationonthe eﬃcacyand speciﬁcity of genedelivery
in mice. N-Alkylated linear PEIs with varying alkyl chain lengths and extent of substitution were synthesized and characterized by
biophysicalmethods.Theirin vivotransfectioneﬃciency,speciﬁcity, andbiodistribution wereinvestigated.N-Ethylation improves
the in vivo eﬃcacy of gene expression in the mouse lung 26-fold relative to the parent polycation and more than quadruples the
ratio of expression in the lung to that in all other organs. N-Propyl-PEI was the best performer in the liver and heart (581- and
3.5-fold enhancements, resp.) while N-octyl-PEI improved expression in the kidneys over the parent polymer 221-fold. As these
enhancementsin gene expression occur withoutchanging the plasmidbiodistribution,alkylationdoes notalter the cellular uptake
but rather enhances transfection subsequent to cellular uptake.
1.Introduction
The promise of gene therapy has yet to be realized for
lack of a safe, eﬃcacious, and speciﬁc delivery vector [1].
Viral vectors are naturally equipped to evoke maximal gene
expression but have failed to prove safety in clinical trials
[1–3]. In contrast, cationic polymers and lipids demonstrate
superior safety but do not aﬀord clinically relevant levels of
gene expression [4–7]. Polyethylenimine (PEI) is considered
a leading polycationic vector for gene delivery [8]. Work
in our lab and others has demonstrated successful in vivo
nucleic acid delivery in mice with various substituted PEIs
[8–10].
Branched PEI ﬁrst emerged as a “gold standard” of
nonviral gene delivery in terms of eﬃcacy but was plagued
by toxicity concerns [11]. Less toxic lower molecular weight
branched PEIs, speciﬁcally those of 2-kDa molecular weight,
failed to aﬀord suﬃcient gene expression [12–15]. However,
N-dodecylation of this PEI dramatically enhanced the pro-
tein expression mediated by it to levelsat least comparable to
thoseofthe25-kDapolycation[16].More recently,linear 22-
k D aP E Ih a se m e r g e da sap r e m i e rP E If o rg e n ed e l i v e r y[ 10,
17]: it exhibits a 21-fold enhancement in protein expression
over leading branched PEIs but with minimal toxicity [10].
In the present study, we synthesized and mechanistically
explored N-alkylated linear PEIs for their ability to enhance
and alter the speciﬁcity of gene delivery in vivo in mice.
We found that covalent derivatization of a small fraction
of PEI’s amino groups with short-chained alkyls enables a
26-fold enhancement of gene expression in the mouse lung
while increasing the amount of expression in this organ
relative to others some 4-fold. Interestingly, the eﬀect of
alkylation varied among tissues and did not alter uptake
of polyplexes into cells; rather, it seemed to aﬀect an
intracellular transfection step.
2.Materialsand Methods
2.1. Chemicals and NMR. Na125I was purchased from Perkin
Elmer. All other chemicals were from Sigma-Aldrich (St.2 Journal of Drug Delivery
Louis, MO) and were of the highest purity available. NMR
spectra were recorded using a Bruker 400-MHz NMR
spectrometer with chemical shifts expressed with reference
to the chloroform peak in CDCl3 (7.24ppm).
2.2. Plasmid and Its Lodination. gWiz Luc encoding the
ﬁreﬂy luciferase gene was purchased from Aldevron (Fargo,
ND). This ready-to-use plasmid, containing the luciferase
gene under the control of a modiﬁed promoter from the
cytomegalovirus immediate early gene, was obtained as a
5.0mg/mL stock solution in water.
Iodination of the plasmid was completed using a modi-
ﬁedversionofpreviouslydescribedmethods[18,19].Brieﬂy,
two iodobeads from Thermo Scientiﬁc (Rockford, IL) were
incubated with 30μL of 0.35M sodium acetate buﬀer, pH
4.0, and 400pmol of Na125I (containing 1mCi of radiation)
at50◦Cfor15min. Tothat,100μgofgW izL uc(in20μL)was
addedandincubatedfor an additional30min. The iodinated
plasmidwaspuriﬁedbysequentialdesaltingonMinitrap and
Miditrap desalting columns (GE Healthcare).
2.3. Linear PEI Synthesis and Its N-Alkylation. Fully deacy-
lated linear PEI of 22-kDa was synthesized from commercial
200-kDa poly(2-ethyl-2-oxazoline), PEOZ, as previously
described [10]. Brieﬂy, 3.0g of the PEOZ was added to
120mL of 24% (w/v) HCl followed by reﬂuxing for 96h.
The PEOZ crystals dissolved completely in 2h, but 3h later
a white precipitate appeared. The solution was brought to
pH 10 with 10M NaOH, isolated by vacuum ﬁltration,
washed with cold water, and lyophilized as the free base. The
resultant white powder was conﬁrmed by NMR to be pure
PEI base.
The linear PEI obtained was reacted with 10mol%
of iodomethane, iodoethane, iodopropane, iodobutane, or
iodooctane in ethanol as previously described [16]. The N-
alkylated crude products, obtained upon rotary evaporation,
were dissolved in water, adjusted to pH 10 with 10M NaOH,
isolated by vacuum ﬁltration, washed with cold water, and
lyophilized. Pure products (∼11% alkyl group substitution)
were obtained as white hygroscopic solids on lyophilization.
1HN M Rs p e c t r o s c o p y( w i t hC D C l 3 as an internal standard)
was used to determine the percent of N-alkylation through
comparison of the integration of the 0.5–1ppm triplet from
the protons of the terminal methyl group of the alkane with
the 2.5–3ppm peak of the polymer’s ethylene protons.
2.4. pH Titration. Acid titrations were carried out using a 1-
mLsolutionofeach N-alkyl-PEI (113mM in–CH2CH2NH–
units) adjusted to pH 11.5 with NaOH. Sequential additions
of 20-μL volumes of 0.5M HCl were performed, and the pH
after each addition was measured; 113mM aqueous NaCl
was titrated similarly as a control using 0.04M HCl. All
experiments were conducted in triplicate.
2.5. Ethidium Bromide (EtBr) Displacement Assay. To a
200μL solutionofgWiz Luc DNA(4.1μg) and EtBr(0.63μg)
in 10mM PBS in a black 96-well plate, 5-μL aliquots of
0.63mM N-alkyl-PEI stock solutions were added sequen-
tially. Fluorescence spectra of free EtBr (FI), of EtBr/DNA
(FD), and of EtBr/DNA after each addition of PEI (FC)
were recorded (λex = 523nm and λem = 587nm). Relative
ﬂuorescence values were calculated using the formula [(FC −
FI)/(FD − FI)] ×100%.
2.6. Gene Delivery in Mice. All animal experiments con-
ducted in this study adhered to the Principles of Laboratory
Animal Care (National Institutes of Health publication no.
85-23, revised in 1985) and were approved by the Institu-
tional Committee on Animal Care. To obtain an N/P ratio
of 8 (that of PEI nitrogen to DNA phosphate), appropriate
volumes of N-alkyl-PEI stock solutions were diluted to
500μL in 5% aqueous glucose and added to an equal volume
of the glucose solutions containing 350μgo ft h ep l a s m i d
DNA (gWiz Luc) followed by pipette mixing. An N/P ratio
of 8 was selected because it was previously determined to
be optimal for linear PEI delivery in vivo in mice. The
resulting polyplexes were incubated at room temperature
for 10min. Then 6- to 8-week-old Swiss Webster female
mice (Taconic Farms) were injected intravascularly via tail
vein with 200μL of the polyplexes containing 70μgo fD N A .
After 24h, the mice were euthanized by CO2 inhalation;
theirlungs,kidneys,livers,hearts, andspleenswerecollected,
washed with PBS, and suspended in lysis buﬀer prepared
by mixing 4mL of 5x passive lysis buﬀer (Promega), 800μL
of 8.7mg/mL phenylmethylsulfonyl ﬂuoride (PMSF) in
methanol, 400μL of protease inhibitor mixture, and 14.8mL
of water. The samples were freeze-thawed, homogenized
by probe-sonication for 40sec in 20-second intervals, and
centrifuged. Then 10μL of the supernatants was mixed
with 100μL of the luciferase assay reagent (Promega), and
the luminescence was measured using an Optocomp I
luminometer (MGM Instruments, Hamden, CT). Protein
concentrationsweredeterminedusingthebicinchoninicacid
(BCA) assay, and the results were expressed as mean ± SD
(n = 4).
2.7. Mouse Perfusion and Radiation Measurements. Poly-
plexes were prepared as described in the previous section. At
5, 10, 15min, or 24h, mice were anesthetized with a lethal
dose of Avertin, the vena cava was cut, a blood sample was
collected, and the animals were perfused with PBS using
a peristaltic pump at a ﬂow rate of about 20mL/min for
5–10min. Once the perfusion ran clear, the organs were
dissected and assayed for gamma counts using 5-minutes
read time. The results were expressed as mean ± SD (n =
4).
3.Resultsand Discussion
While much has been done to improve its transfection eﬃ-
ciency,linearPEI,currentlya“goldstandard” ofpolycationic
gene delivery, still falls short of characteristics required for
clinical utility. In this work, we prepared a series of N-
alkylated linear PEI derivatives with the goal of developing
am o r ee ﬃcient and speciﬁc vector for in vivo transfection.Journal of Drug Delivery 3
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Figure 1: The eﬀect of N-alkylation on the buﬀer capacity and DNA binding eﬃciency of linear PEI. (a) Acid titration proﬁles of aqueous
solutionsoftheunderivatized PEI(solidsquares),methyl-PEI(opensquares),ethyl-PEI (solidtriangles),propyl-PEI (opentriangles),butyl-
PEI (solid circles), octyl-PEI (open circles), and NaCl as a control (× symbols). The corresponding 113mM solutions were adjusted to pH
11.5 at room temperature and then titrated with 0.5M HCl (0.04M in the case of NaCl). (b) Displacement of the intercalated ﬂuorophore
EtBr from plasmid DNA by the underivatized PEI (solid squares), methyl-PEI (open squares), ethyl-PEI (solid triangles), propyl-PEI (open
triangles), butyl-PEI (solid circles), and octyl-PEI (open circles). N/P ratio is that between the nitrogen atoms in the polycation and the
phosphate groups of the bases in the plasmid.
In particular, methyl-PEI, ethyl-PEI, propyl-PEI, butyl-PEI,
and octyl-PEI were synthesized from the corresponding
iodoalkanes and fully deacylated linear PEI. Alkylation
conditions were optimized to derivatize approximately 11%
of the backbone amines for all derivatives (as determined
by H1 NMR spectroscopy). This level of modiﬁcation was
experimentally determined to be the highest (and most
eﬃcacious) degree of substitution that did not result in
precipitation of the polyplexes.
The ability to buﬀerendosomes/lysosomes and condense
DNA is a necessary requirement for eﬃcient gene delivery
by polycationic vectors. To assess the eﬀect of N-alkylation
on the ability of PEI to mediate these steps, the PEIs were
characterized by acid titration and ethidium bromide (EtBr)
displacement from plasmid DNA. As seen in Figure 1(a),
all N-alkylated PEIs retain signiﬁcant buﬀering capacity.
Likewise, the derivatives all condense plasmid DNA to an
appreciable degree (Figure 1(b)). Underthe conditionsused,
polyplexes are stable for at least 1h.
It is interesting to note that N-ethyl-PEI demonstrates
reduced DNA condensation and buﬀering capacity, suggest-
ing that the ﬂuid phase dynamics and DNA interactions
of alkylated polyamines is complicated and further research
is required to fully understand the relationship between
the chemical structure of N-alkylated linear PEIs and their
biophysical properties. This sentiment has been mirrored for
otherpolyionicgenedeliverysystemsinrecentyears[20–22].
Bothcondensation/decondensationofDNAandendoso-
mal/lysosomal buﬀering are critical steps in cell transfection
[7, 23]; while ideal conditions for these steps have not been
established, it is known that eﬀective DNA condensation to
form polyplexes and subsequent decondensation inside the
cell are in direct competition [24]. Therefore, these data
alone are not suﬃcient to predict the transfection properties
of ethyl-PEI or any of the other N-alkylated PEI derivatives
[25].
Since our unpublished work pointed to a lack of
correlation between in vitro (i.e., in cell culture) and in vivo
(i.e., in animal models) PEI-mediated gene expression, the
N-alkylated linear PEI derivatives were investigated for their
ability to eﬃciently and speciﬁcally transfect cells only in
vivo. Figure 2 depicts the gene expression proﬁles in mice
of the parent linear PEI and its N-alkylated derivatives. One
can see that in the lung, the tissue which demonstrates over
96% of all luciferase expression for the parent polycation,
methyl-PEI, ethyl-PEI, and propyl-PEI exhibited enhanced
luciferase expression relative to the parent by 8-, 26-,
and 7-fold, respectively (Figure 2(a)). In contrast, longer
alkyl chains negatively aﬀected the transfection eﬃciency:
while pulmonary luciferase expression mediated by butyl-
PEI is marginally reduced, octyl-PEI demonstrates 200-
fold lower expression in the lung than the unmodiﬁed PEI
(Figure 2(a)).
Interestingly, the other mouse tissues examined each
demonstrate a unique expression proﬁle with respect to the
alkyl chain length (Figure 2). In the heart and liver, propyl-
PEI performs the best by 3.5-and 581-fold, respectively, over
the parent polycation (Figures 2(b) and 2(d))w h i l ei nt h e
kidneys longer alkyl chain mediates enhanced gene expres-
sion with octyl-PEI providing 221-fold greater expression
than unmodiﬁed PEI (Figure 2(e)). In the spleen, ethyl- PEI
and octyl- PEI produce similar levels of luciferase expression
that are twice those of the parent’s (Figure 2(c)). It is unclear
why this unique trend is observed in the spleen, warranting
further investigation.
The changes in the luciferase expression proﬁle can be
summarized by the ratio of expression in the lungs relative
to all other organs combined. While for the parent PEI that4 Journal of Drug Delivery
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Figure 2: Comparison of the gene expression in the lungs (a), heart (b), spleen (c), liver (d), and kidneys (e) of a plasmid containing the
luciferase gene mediated by the following N-alkylated linear PEI derivatives: (i) unmodiﬁed, (ii) methyl, (iii) ethyl, (iv) propyl, (v) butyl,
and (vi) octyl.
S
p
e
c
i
ﬁ
c
a
c
t
i
v
i
t
y
(
R
L
U
/
1
0
s
/
m
g
)
0
1
2
3
0 5 11 14 20
N-alkylation (%)
Figure 3: Gene expression in the lungs of a plasmid containing the
luciferase gene mediated by N-ethyl-PEI as a function of the degree
of the polycation’s alkylation.
ratio is 28:1, it jumps to 119:1 and 117:1, respectively, for
the methyl and ethyl derivatives. For the three remaining
derivatives(propyl-PEI,butyl-PEI,andoctyl-PEI),however,
the ratio drops to 15:1, 2:1, and 0.06:1, respectively . In
the octyl-PEI-mediated delivery, where lung expression does
not dominate, maximal expression is seen in the spleen. This
suggests that N-alkylation canbeused tomodulatetheorgan
speciﬁcity of gene expression.
Given the dramatic diﬀerences in protein expressions
across mouse organs with 11% alkylation, we investigated
the eﬀect of varying degrees of N-alkylation with the best
performing ethyl-PEI.AsseeninFigure 3,the11%alkylation
happens to produce the most eﬃcient gene expression
in the lungs as compared with the 5%, 14%, and 20%
derivatization. Higher degrees of N-alkylation of linear PEI
were not tested dueto drastically diminished solubilityofthe
resultant polycations.Journal of Drug Delivery 5
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Figure 4: (a) Pharmacokinetic proﬁle of 125I-labeled gWiz Luc plasmid DNA with no delivery vector with an initial dose of 70μgo ft h e
plasmid containing approximately 1μCi of radiation. (b) Comparison of the organ biodistribution of 125I-labeled plasmid containing the
luciferase gene complexed with no vector (black), linear PEI (light grey), and N-ethylated linear PEI (dark grey) at 15minutes.
Table 1: Biodistribution of 125I-labeled gWiz Luc plasmiddelivered
with linear PEI and its N-alkylated derivatives. Values are the
percentages of injected dose still remaining in select tissues at 24h.
Polycation Spleen Kidney Liver Lung Heart Blood
unmodiﬁed PEI 0.03 0.11 0.49 0.01 0.00 0.02
N-methyl-PEI 0.02 0.08 0.30 0.01 0.00 0.03
N-ethyl-PEI 0.02 0.12 0.30 0.02 0.01 0.06
N-propyl-PEI 0.02 0.11 0.30 0.01 0.00 0.03
N-butyl-PEI 0.02 0.09 0.29 0.01 0.00 0.03
N-octyl-PEI 0.03 0.05 0.27 0.01 0.00 0.01
Since protein expression is ultimately required for gene
therapy to become a clinical reality, it is an appropriate
endpoint measurement. However, it is also of mechanistic
interest to establish in what organ the delivered plasmid
ends up. To this end, we treated mice with 125I-labeled DNA
in complexes with the N-alkylated linear PEI derivatives
to follow the localization of the delivered plasmid. The
biodistribution of the polyplexes was determined in vivo at
2 4 h ,t h et i m ep o i n to ft h ee ﬃciency study, as shown in
Table 1. At24h, most ofthe plasmid had beenexcreted; what
remained resided predominantly in the clearance organs,
speciﬁcally the kidneys and liver (0.1–0.5% of injected dose
for the best transfecting ethyl-PEI). Less than 0.01% of the
injected dose remained in the lung at 24h regardless of the
delivery vector.
Elucidating the biodistribution of the plasmid at an
earlier time point may be critical to understanding the
eﬀect of N-alkylation of linear PEI on localization of the
delivered plasmid. Since the biodistribution of naked plas-
mid and PEI-mediated plasmid delivery were identical, the
pharmacokinetics of naked plasmid clearance was evaluated
to determine the optimal time point for this analysis. As seen
in Figure 4(a), nearly 80% of the free plasmid was cleared
f r o mc i r c u l a t i o ni nj u s t5 m i na n ds o m e9 0 %a t1 5 m i n .
Giventherapidclearancefromtheblood,thebiodistribution
was subsequently assessed at 15min.
As seen in Figure 4(b), the tissue distribution of naked
plasmid DNA, linear PEI, and the most competent N-
alkylated derivative (ethyl-PEI) at 15min is very similar to
that at 24h. The kidneys and liver retained the greatest
percentages of delivered radiation (about 2% of the injected
dose each for ethyl-PEI) while the lung retained much less
(only 0.35% of the injected dose). Interestingly, delivery
of plasmid via a polycationic vector does not change the
biodistribution of the plasmid at either 15min or 24h as
compared to naked plasmid. Moreover, even clearance from
the blood occurs at the same rate.
We previously hypothesized that enhanced interactions
with cell membranes due to increased hydrophobicity stem-
ming from N-alkylation of branched PEI could enhance
polyplex uptake and subsequent gene expression [16].
However, studies described herein revealed no appreciable
change in the biodistribution of free plasmid DNA relative
to that delivered with a vector, either linear PEI itself or
its N-ethylated derivative. The localization of 125I-labeled
plasmid DNA is similar across all tissues and all polycationic
vectors at 24h and across all those investigated at 15min
(Figure 4(b)). This suggests that at least in the case of
linear PEI, its N-alkylation does not enhance uptake of the
polyplexesandinsteadplayssomeother,yettobedetermined
role.
Note that expression of protein from delivered plasmid
DNA requires the successful completion of several steps: (i)
uptakeby endocytosis; (ii) endosomal/lysosomal escape; (iii)
transport to,and uptakeby, the nucleus;(iv)decondensation
of DNA from the polycation; (v) transcription and trans-
lation of delivered plasmid. Given the changes to buﬀering
capacity and DNA condensation seen with N-ethylated PEI
and the greatly enhanced protein expression observed as a
result, it is likely that either the second or the fourth of these
steps is enhanced by ethylation.6 Journal of Drug Delivery
4.Conclusions
In closing, herein we have examined in vivo transfection
eﬃciency,speciﬁcity, and biodistributionofa model plasmid
mediated by N-alkylated linear PEIs with varying alkyl
chain lengths and extent of substitution. While N-ethylation
greatlyimprovesthe eﬃcacy of gene expression in the mouse
lung relative to that by the parent polycation, N-propyl-
PEI and N-octyl-PEI are dramatically better performers
than PEI in the liver and kidneys, respectively. Since these
enhancements in gene expression occur without changing
the plasmid biodistribution, we conclude that alkylation
of PEI enhances transfection subsequent to cellular uptake
rather than the latter process itself.
Abbreviations
PEI: Polyethylenimine
EtBr: Ethidium bromide.
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